Skip to Main Content

Paper Details

Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Mol Oncol
3
2022
AR, H3K4, KDM5D, LAPC4, LNCaP, LNCaP cell line, MYBL2, MYBL2 mRNA, MYBL2-, androgen, androgen receptor, androgen receptor (AR)-positive hormone-sensitive prostate cancer cell lines, androgen-sensitive human prostate adenocarcinoma, binding sites, cabazitaxel, cell, cell line, docetaxel, histone H3, histone demethylase KDM5D, hormone-sensitive prostate cancer, lysine, lysine-specific demethylase 5D, men, metastatic disease, prostate cancer, prostate cancer cells, taxanes
Author NameAffiliation
Elai DavicioniDecipher Biosciences Inc.
Michael A CarducciSidney Kimmel Cancer Center, Johns Hopkins Medical Institutions
Philip W KantoffMemorial Sloan Kettering Cancer Center
Philip W KantoffMemorial Sloan Kettering Cancer Center
  • 1 - 4

Datasets

Release 1.2